Compass Therapeutics, Inc. (CMPX) intrinsic value & 10-year financials
Compass Therapeutics, Inc. (CMPX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue reached to $0, with an average return on invested capital of -2889.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.86
- Market cap
- $118.2M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -2889.4%
- Free cash flow (FY2025)
- -$49.2M
CMPX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$66.5M | — | -$49.2M | — | -55.4% |
| FY2024 | $850.0K | -$49.4M | — | -$44.9M | -6661.8% | -53.2% |
| FY2023 | $0 | -$42.5M | — | -$40.6M | — | -36.8% |
| FY2022 | — | -$39.2M | — | -$34.3M | — | -56.6% |
| FY2021 | — | -$82.2M | — | -$21.2M | — | -20093.7% |
| FY2020 | — | -$29.5M | — | -$26.9M | — | 43.9% |
| FY2019 | — | -$34.7M | — | -$32.2M | — | 26.4% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Compass Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Compass Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -47.5% ROIC.
Compass Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Compass Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.